Carvedilol Tablets — Class III drug recall D-0263-2022
Terminated recall by Aurobindo Pharma USA Inc., reported 2021-12-01, distributed nationwide. Failed Impurities/Degradation Specifications
| Recall number | D-0263-2022 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Aurobindo Pharma USA Inc., East Windsor, NJ, United States |
| Recall initiated | 2021-11-15 |
| Classified | 2021-12-01 |
| Reported by FDA | 2021-12-01 |
| Terminated | 2023-08-23 |
| Distributed | Nationwide (US) |
| Quantity | 7,296 containers |
| Reason classes | specification failure |
| NDC | 65862-0142, 65862-0142-01, 65862-0142-05, 65862-0142-99, 65862-0143, 65862-0143-01, 65862-0143-05, 65862-0143-99, 65862-0144, 65862-0144-01, 65862-0144-05, 65862-0144-99, 65862-0145, 65862-0145-01, 65862-0145-05, 65862-0145-99 |
| Lot numbers | QG0619030-A |
| Expiration dates | 2022-11 |
Product
Carvedilol Tablets, USP, 6.25 mg, 500 Tablets bottle, Rx Only, Distributed by: Aurobindo Pharma USA Inc., 279 Princeton-Hightstown Road, East Windsor, NJ, 08520, Made in India, NDC 65862-143-05
Reason for recall
Failed Impurities/Degradation Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0263-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.